Reply to Comment on "Market Exclusivity for Drugs with Multiple Orphan Approvals (1983-2017) and Associated Budget Impact in the US"

被引：0

作者：

Padula, William V. ^{[1
,2
]}

Parasrampuria, Sonal ^{[3
]}

Socal, Mariana P. ^{[3
]}

Conti, Rena M. ^{[4
]}

Anderson, Gerard F. ^{[3
]}

机构：

[1] Univ Southern Calif, Sch Pharm, Dept Pharmaceut & Hlth Econ, USC Schaeffer Ctr, 635 Downey Way, Los Angeles, CA 90089 USA

[2] Univ Southern Calif, Leonard D Schaeffer Ctr Hlth Policy & Econ, Los Angeles, CA 90007 USA

[3] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA

[4] Boston Univ, Inst Hlth Syst Innovat & Policy, Questrom Sch Business, Boston, MA 02215 USA

来源：

关键词：

D O I：

10.1007/s40273-020-00973-9

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

引用

页码：1375 / 1376

页数：2

共 5 条

[1] Comment on "Market Exclusivity for Drugs with Multiple Orphan Approvals (1983-2017) and Associated Budget Impact in the US"
Manning, Richard
PHARMACOECONOMICS, 2020, 38 (12) : 1373 - 1374
[2] Market Exclusivity for Drugs with Multiple Orphan Approvals (1983-2017) and Associated Budget Impact in the US
Padula, William V.
Parasrampuria, Sonal
Socal, Mariana P.
Conti, Rena M.
Anderson, Gerard F.
PHARMACOECONOMICS, 2020, 38 (10) : 1115 - 1121
[3] Reply to Comment on “Market Exclusivity for Drugs with Multiple Orphan Approvals (1983–2017) and Associated Budget Impact in the US”
William V. Padula
Sonal Parasrampuria
Mariana P. Socal
Rena M. Conti
Gerard F. Anderson
PharmacoEconomics, 2020, 38 : 1375 - 1376
[4] Comment on “Market Exclusivity for Drugs with Multiple Orphan Approvals (1983–2017) and Associated Budget Impact in the US”
Richard Manning
PharmacoEconomics, 2020, 38 : 1373 - 1374
[5] Market Exclusivity for Drugs with Multiple Orphan Approvals (1983–2017) and Associated Budget Impact in the US
William V. Padula
Sonal Parasrampuria
Mariana P. Socal
Rena M. Conti
Gerard F. Anderson
PharmacoEconomics, 2020, 38 : 1115 - 1121